Table 1.
Clinical characteristics of the patients at baseline and at year 1 a
| Characteristics | Baseline | Year 1 |
|---|---|---|
| Male sex, n (%) |
67 (92%) |
– |
| Age, years |
58 (49 to 65) |
– |
| Pacific ethnicity, n (%) |
25 (34%) |
– |
| Māori ethnicity, n (%) |
18 (25%) |
– |
| European and other ethnicities, n (%) |
30 (41%) |
– |
| Gout disease duration, years |
23 (16 to 28) |
– |
| Flare frequency (in the preceding three months) |
0 (0 to 2) |
0 (0 to 2) |
| Allopurinol use, n (%) |
62 (85%) |
62 (85%) |
| Allopurinol dose (n = 62), mg/day |
300 (200 to 300) |
300 (200 to 300) |
| Colchicine use, n (%) |
33 (45%) |
32 (44%) |
| Nonsteroidal anti-inflammatory drug use, n (%) |
46 (63%) |
44 (60%) |
| Prednisone use, n (%) |
11 (15%) |
12 (16%) |
| Health assessment questionnaire II score |
0.2 (0 to 0.55) |
0.15 (0 to 0.58) |
| Swollen joint count |
0 (0 to 0) |
0 (0 to 0) |
| Tender joint count |
0 (0 to 1) |
0 (0 to 1) |
| Number of subcutaneous tophi |
3 (2 to 9) |
3.5 (2 to 8) |
| Serum creatinine, μmol/L |
99 (84 to 112.5) |
96 (81 to 112) |
| C-reactive protein, mg/L |
2.4 (1 to 5) |
2.1 (1 to 6) |
| Serum urate, mmol/L |
0.36 (0.18 to 0.46) |
0.37 (0.32 to 0.46) |
| Serum urate <0.36 mmol/L, n (%) |
34 (47%) |
29 (40%) |
| Serum urate <0.36 mmol/L at both time points, n (%) | 21 (29%) | |
aUnless otherwise specified, data are presented as medians (IQRs).